This article was originally on a blog post platform and may be missing photos, graphics or links. See About archive blog posts. The Centers for Disease Control and Prevention’s Advisory Committee on ...
GlaxoSmithKline’s FDA approval for Cervarix, received last week as rival Merck expanded its Gardasil label, heralds a market-share battle that may hinge on science. Cervarix is approved to protect ...
GlaxoSmithKline's (GSK) cervical cancer vaccine, Cervarix, was today confirmed by the Netherlands Vaccine Institute (NVI) as the cervical cancer vaccine for the Dutch National Immunisation Programme ...
Issued: October 21, 2009, Philadelphia, PA - GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices ...
The World Health Organization has approved a second cervical cancer vaccine, this one made by GlaxoSmithKline, meaning U.N. agencies and partners can now officially buy millions of doses of the ...
The pursuit to become the top-selling cervical cancer vaccine intensified last week as GlaxoSmithKline submitted its Biologics License Application (BLA) for Cervarix with the FDA. Cervarix is being ...
The FDA has another delay for this HPV vaccine. Because of its large-cap pharma size, Glaxo provided few details about any additional information the FDA might want on Cervarix. Most importantly, the ...
This article was originally on a blog post platform and may be missing photos, graphics or links. See About archive blog posts. For the record: An earlier version of this story and its headline ...
The FDA has approved Cervarix (human papillomavirus bivalent [types 16 and 18] vaccine, recombinant, from GlaxoSmithKline) for the prevention of cervical pre-cancers and cervical cancer associated ...
NEW YORK, Nov 12 (Reuters) - GlaxoSmithKline Plc's cervical cancer vaccine Cervarix should eventually secure a 50 percent market share, despite being second to market, the group's chief executive said ...
WASHINGTON – Federal health officials said Wednesday a long-delayed vaccine from GlaxoSmithKline successfully blocks the leading virus that causes cervical cancer in women. The Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results